Project Grant R01CA315681
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $598K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded University of Maryland, Baltimore $399,829 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of a novel enhancer RNA (CYP11A1-eRNA) in castration-resistant prostate cancer progression. The research defines mechanisms by which CYP11A1-eRNA regulates androgen receptor target gene expression and evaluates whether the enhancer RNA promotes androgen-independent prostate cancer cell...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $995,981 on September 9, 2025, under the Cancer Biology Research program (CFDA 93.396) to decipher the role of cancer pain-associated neuronal activity in driving malignancies, with work continuing through August 31, 2030. The research addresses the hypothesis that a feedforward mechanism exists between cancer pain-associated sensory neuron hyperactivity and malignant peripheral nerve sheath tumor (MPNST)...
- The National Cancer Institute awarded the University of Arizona $545,195 under the Cancer Biology Research program (CFDA 93.396) on July 10, 2026, to interrogate niche-specific nuclear and extra-nuclear estrogen receptor-alpha (ER) signaling to prevent ER+ breast cancer progression in bone. The project will identify tumor versus bone niche-specific and ER pathway-specific, tumor-promoting effects of ER signaling using a human breast cancer bone metastasis model combined with pharmacologic and...
- The National Cancer Institute awarded the University of Arizona $544,929 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of estrogen receptor in regulating breast cancer cell invasion. The research examines how matrix stiffness and estrogen act as critical regulators of estrogen receptor-positive (ER+) breast cancer invasion in the tumor microenvironment. The work focuses on mechanohormonal conditioning—the interplay between a tumor cell's...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, Baltimore a $2.84M Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate improved cancer treatment methodologies. The award, effective August 18, 2025 through July 30, 2029, funds research focused on enhancing the therapeutic efficacy of cyclophosphamide (CPA) and doxorubicin (DOX)-based chemotherapy regimens while minimizing treatment-related toxicity....
- The National Cancer Institute awarded the University of Texas at El Paso $573,746 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of N6-methyladenosine (M6A) modification in estrogen receptor activation and breast cancer progression. The research examines how M6A modification of enhancer RNAs facilitates phase-separated condensation of estrogen receptors, which is critical for assembling enhancer transcriptional machinery and regulating...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $399,829 to the University of Maryland, Baltimore on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop protein degradation strategies that overcome menin drug resistance in acute leukemias. The project addresses rapid drug resistance to menin inhibitors in clinical trials for MLL-rearranged (MLLR) leukemias, which carry a dismal prognosis...
- The National Cancer Institute awarded the University of Illinois $677,197 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a Phase III randomized controlled trial evaluating acupuncture's effects on psychoneurological symptoms in breast cancer survivors undergoing endocrine therapy. The research will compare 10 acupuncture sessions delivered over 6 weeks against sham acupuncture and usual care in a cohort of 252 breast cancer survivors. The trial...
- Federal Project Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $434,542 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a Drosophila (fruit fly) model for studying aromatase inhibitor (AI)-induced musculoskeletal pain. The research addresses a significant clinical gap in breast cancer treatment, as approximately 40% of post-menopausal women receiving AI therapy (letrozole, anastrozole, or exemestane)...
- The National Cancer Institute, an institute of the Department of Health and Human Services National Institutes of Health, awarded New York University $667,815 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research examining protease composition and concentration in the oral cancer tumor microenvironment and their relationship to pain heterogeneity. The award funds investigation of how protease-activated receptor 2 (PAR2) activating proteases contribute...